Intel, FedEx downgraded: Wall Street’s top analyst calls

Oppenheimer downgraded Incyte (INCY) to Perform from Outperform with a price target of $82, up from $81. The firm cites the high expectations for Opzelura, povorcitinib, mCALR, CDK2i, and new management for the downgrade.